Evidence map›Paper›PMID 36775822›Full record

ArticleEpidemiology and infection2023

Seroprevalence of COVID-19 infection in a densely populated district in the eastern Democratic Republic of Congo.

Leonid M Irenge, Homer M Bulakali, Arthur Irenge Akonkwa, Jérôme Ambroise, Jean-Luc Gala

Open access · goldAbstract read
In one paragraph

Article in Epidemiology and infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Leonid M IrengeCenter for Applied Molecular Technologies, Institute of Clinical and Experimental Research, Université catholique de Louvain, Brussels, Belgium.
Homer M BulakaliPolyclinique Berna, Avenue Nyamulagira, 52 Kadutu/Bukavu, DR Congo.
Arthur Irenge AkonkwaPolyclinique Berna, Avenue Nyamulagira, 52 Kadutu/Bukavu, DR Congo.
Jérôme AmbroiseCenter for Applied Molecular Technologies, Institute of Clinical and Experimental Research, Université catholique de Louvain, Brussels, Belgium.ORCID 0000-0002-1218-6143
Jean-Luc GalaCenter for Applied Molecular Technologies, Institute of Clinical and Experimental Research, Université catholique de Louvain, Brussels, Belgium.ORCID 0000-0002-7749-573X
UCLouvain · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Data on coronavirus disease 2019 (COVID-19) prevalence in the Democratic Republic of Congo are scarce. We conducted a cross-sectional study to determine the seroprevalence of antibodies against anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the slum of Kadutu, city of Bukavu, between June and September 2021. The survey participants were all unvaccinated against SARS-CoV-2. The crude seroprevalence rate was adjusted to the known characteristics of the assay. Participants aged 15-49 years old made up 80% of the population enrolled in the study (

Indexed as

COVID-19AdolescentAdultAntibodiesAntibodies, ViralCross-Sectional StudiesDemocratic Republic of the CongoFemaleHumansMaleMiddle AgedSARS-CoV-2Seroepidemiologic StudiesYoung AdultAntibodiesAntibodies, ViralCOVID-19 infectionDRCSARS-CoV-2seroprevalenceurban settlement

Identifiers

PMID36775822
PMCPMC9947032
OpenAlexW4318825580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.